Yaron Werber

Yaron Werber News

• 

  Drug Approvals Hit a Seven-Year High in 2011 on Improved Data

  U.S. approvals of new drugs hit a seven-year high last year as pharmaceutical companies responded to regulators’ demands for better safety data and avoided last- minute requests for more information.

• Pharmasset Says Drug Trial Change Won’t Affect Gilead Takeover Agreement

  Pharmasset Inc., the company that has agreed to be bought by Gilead Sciences Inc., said it will modify the design of a hepatitis-C trial after one of its experimental drugs was linked to liver-function abnormalities.

• Regeneron Wins FDA Approval for Blindness Drug Eylea

  Regeneron Pharmaceuticals Inc. won U.S. approval of Eylea, a treatment for a common cause of blindness that will rival Roche Holding AG’s Lucentis.

• Regeneron Surges on VA Order to Drop Avastin for Eyes

  Regeneron Pharmaceuticals Inc. shares surged to a 20-year high on a Department of Veterans Affairs decision to stop using Roche AG’s cancer drug Avastin to treat an eye disease as it investigates reports of serious infections and blindness.

• Amgen Bone Drug Denosumab Cleared to Treat Fractures in Cancer Patients

  Amgen Inc. ’s osteoporosis drug denosumab was approved by U.S. regulators for reducing fractures in prostate and breast cancer patients, an indication that may boost sales to $2.4 billion in five years.

• 

  Sanofi May Make Hostile Bid If Genzyme Resists, Citigroup Says

  Sanofi-Aventis SA may begin a hostile bid for Genzyme Corp. should the U.S. biotechnology company resist a takeover approach, analysts at Citigroup Inc. said.

• 

  Novartis's Multiple Sclerosis Pill Faces FDA Review

  Novartis AG ’s drug Gilenia has risks that may outweigh its benefit in treating multiple sclerosis, according to U.S. regulators reviewing whether to approve the first pill to slow progression of the disease.

• 

  Novartis’s $48,000 Pill Spurs U.S. Price Increases for Older MS Treatments

  The prices of multiple sclerosis medicines have risen as much as 39 percent since last year, even as competition intensified with the introduction of the first pill to treat the disease.

• 

  Amgen, Genzyme Gain Time Under Medicare Billing For Oral Dialysis Drugs

  Amgen Inc. , the world’s largest biotechnology company, and Genzyme Corp. will be able to separately bill Medicare for oral drugs used in dialysis until 2014, longer than first proposed. The shares rose.

• AMAG Board Says Shareholders Should Vote for Allos Purchase

  AMAG Pharmaceuticals Inc., the maker of the anemia drug Feraheme, urged investors today to support its $189 million bid for cancer drugmaker Allos Therapeutics Inc. over the objections of MSMB Capital Management.

Quote

• "It's a positive for Eylea."

  - Yaron Werber on Sep 21, 2011

Related Topics

• 

  New York

• 

  Food And Drug Administration

• 

  Washington

Most Popular on Bloomberg

• S&P 500 Gains as Banks Rally; Euro Falls on Draghi Speech

• Euro Falls as Draghi Says ECB Prepared to Act; Ringgit Rises

• S&P 500 Velocity Seen in Best Defensive Rally Since 2011

• GM Plans About $16 Billion in Investments in U.S. by 2016

• Gold Bulls Split With Buffett as Traders Say Sell: Commodities

Yaron Werber Videos